Allied Health & Imaging · Independent exam preparation
CCTC® Preparation Guide: Clinical Transplant Coordination Study Guide
Practise transplant education, candidate evaluation, matching, medication safety, surgical-complication assessment, graft monitoring and urgent triage through focused CCTC concepts and original drills.
By CertMedbry · Updated 31 October 2026
Learn to explain transplant choices, identify evaluation barriers, interpret matching information, recognize graft dysfunction and coordinate safe follow-up. This selective guide develops 60 substantive concepts across the CCTC outline effective July 1, 2026, using a 19/18/23 domain distribution. The official ABTC detailed content outline defines the full examination scope, including adult, pediatric and multiorgan transplantation involving kidney, pancreas, liver, heart, lung and intestine. Use the guide alongside that outline to identify additional organ-specific study needs.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
How many questions are on the CCTC examination, and how long is it?
The handbook specifies 175 items: 150 scored items and 25 unscored pretest items. Testing time is three hours. Pretest responses do not contribute to the score. Breaks do not add testing time.
ABTC Candidate Handbook — currently linked August 13, 2026 PDF
How is the examination delivered, and what question styles are verified?
The handbook describes computer delivery at PSI test centers, with international centers available by arrangement. Items are multiple choice with four answer options. Candidates can change answers, move backward, leave items unanswered temporarily and bookmark items. The handbook describes examination forms and does not identify computer-adaptive delivery. Confirm available delivery arrangements with ABTC and PSI.
ABTC Candidate Handbook — currently linked August 13, 2026 PDF
Which blueprint applies to this guide?
The CCTC outline effective July 1, 2026 applies. The currently linked handbook has an August 13, 2026 filename; that filename date is separate from the outline's effective date. Published domains are Transplant Education, 31% and 46 scored items; Pre-Transplant Evaluation and Management, 30% and 46 items; and Post-operative Monitoring, Evaluation, and Reporting, 39% and 58 items. The printed percentages and counts are retained despite rounding. The earlier outline effective until June 30, 2026 is historical.
ABTC Candidate Handbook — currently linked August 13, 2026 PDF · ABTC Candidate Handbook — March 12, 2026 PDF
What professional level and eligibility does CCTC represent?
ABTC describes examinations assessing competencies expected of a minimally competent first-year transplant professional. Its certification page specifies 12 months of clinical vascular organ coordinator work experience for CCTC eligibility. CCTC is a professional certification, not an RN or advanced practice nursing licensure examination. CCTN has separate registered nurse experience requirements; CPTC, CTP and CTFC assess other professional roles.
ABTC Certification Examinations · ABTC Candidate Handbook — currently linked August 13, 2026 PDF
Does experience with one organ cover the examination's full scope?
ABTC expects awareness of other organ practices and basic adult and pediatric principles even when a candidate works with one organ. The scored-item secondary specifications contain 75 general and 75 organ-specific items, including kidney, liver, heart, lung, pancreas, intestine and combined transplants. This 60-concept guide is selective; the official outline remains the complete scope reference.
ABTC Candidate Handbook — currently linked August 13, 2026 PDF
What passing score and practice-test interpretation are supported?
The handbook explains standard setting, equating and overall pass/fail decisions. A numerical passing percentage should not be inferred from practice questions. Domain subscores require caution because they contain fewer items. The 20 original questions here are independent learning drills; their results do not predict certification success.
ABTC Candidate Handbook — currently linked August 13, 2026 PDF
Which jurisdiction and clinical publication dates matter?
OPTN requirements discussed here are U.S. requirements, using the policy compilation effective October 1, 2026. The clinical references include KDIGO candidate guidance from 2020, a kidney recipient summary from 2009, PROGRAF labeling revised July 2021 and ISHLT heart recipient guidance published in 2023. Publication dates should not be confused with blueprint dates. Organ-specific protocols and current legal requirements require their own applicable references.
OPTN Policies — effective October 1, 2026 · KDIGO 2020 Guideline on Evaluation and Management of Candidates for Kidney Transplantation · KDIGO 2009 Kidney Transplant Recipient Guideline: Summary · PROGRAF Prescribing Information — revised July 2021 · ISHLT Guidelines for the Care of Heart Transplant Recipients — published May 2023
These independently authored learning materials address ABTC's Certified Clinical Transplant Coordinator examination and first-year coordinator competence. CCTC is separate from ABTC's transplant nursing, procurement, preservationist and financial coordinator credentials. Clinical guidance supports the clinical teaching; the ABTC outline establishes examination scope.
Outline used: Current ABTC-linked Candidate Handbook, filename dated August 13, 2026; CCTC detailed content outline effective July 1, 2026. Verified for the requested reference date of October 12, 2026, Asia/Hong_Kong. The workbook label matches the official credential; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Transplant Education31%
1.How should kidney replacement choices be compared?
Kidney transplantation can replace kidney function and improve daily life, but it introduces surgery, rejection risk and ongoing immunosuppression. Hemodialysis and peritoneal dialysis also replace some kidney functions, with different treatment schedules and practical demands. Education should compare how each option fits the person's health, support and preferences. The discriminating issue is the balance of benefits and burdens for that individual, rather than assuming that one treatment is immediately available or suitable for everyone.
Apply it
A patient wants fewer treatment visits but fears surgery. Ask which daily activities matter most, compare home and center dialysis with transplantation, and clarify that evaluation determines suitability without obligating the patient to accept surgery.
Common pitfall: Describing transplantation as a cure can obscure continuing treatment obligations. Presenting dialysis as a single uniform option also conceals meaningful differences in setting and workload.
2.What does conservative kidney management aim to achieve?
Conservative management treats kidney failure without dialysis or transplantation, emphasizing symptom relief, quality of life and support for the person's goals. It includes active medical care and planning rather than abandonment. The key educational distinction is between replacing kidney function and managing the consequences of kidney failure without replacement therapy. A useful discussion explores expected burdens, symptoms, support needs and the patient's priorities, while checking that the choice is informed and voluntary.
Apply it
An older patient with substantial illness says hospital-based treatment would undermine the time they value at home. Explain conservative management alongside replacement therapies and arrange a goals-focused discussion that includes symptom treatment and family support.
Common pitfall: Equating conservative management with receiving no care can pressure patients toward unwanted treatment. Conversely, discussing comfort alone without explaining replacement alternatives prevents an informed comparison.
3.How does teach-back reveal an unsafe understanding?
Teach-back asks a patient to explain instructions in their own words or demonstrate a task. It checks the clarity of the teaching rather than testing the patient's intelligence. A statement such as 'I understand' cannot establish that the patient can perform the required action. When an explanation reveals a gap, simplify the information, reteach the relevant part and ask again. The decisive evidence is accurate explanation or demonstration, not agreement or confidence.
Apply it
After medication teaching, a recipient says the antirejection medicine can stop when laboratory results normalize. Explain its continuing purpose in plain language, then ask the patient to describe what they will do when they feel well.
Common pitfall: Repeating the same explanation more loudly does not address a misunderstanding. Asking only whether the patient has questions can leave important errors undiscovered despite polite reassurance.
4.How should education accommodate language and literacy needs?
Accessible education matches the person's language, reading ability, sensory needs and capacity to process information. Living donor consent requires understandable information, including appropriate language assistance when needed. Plain wording, manageable segments and explanation in the person's own words help establish comprehension. The discriminating cue is a communication barrier that can be addressed, rather than evidence that the person cannot participate in a decision. Written materials support discussion but cannot replace an understandable consent conversation.
Apply it
A prospective donor reads little English and nods throughout teaching. Arrange appropriate interpretation, provide understandable materials and discuss donation privately. Ask the donor to explain major risks and the option to withdraw before assessing comprehension.
Common pitfall: Treating a signed translated form as proof of understanding overlooks the conversation itself. A relative's fluency also does not establish the donor's comprehension or freedom from pressure.
OPTN Guidance for the Informed Consent of Living Donors · AHRQ Tool: Teach-Back
5.What makes living donor risk disclosure complete?
Living donation exposes a person without a therapeutic need for the operation to physical, psychological and financial risks. Consent should address the evaluation, operation, recovery, possible short-term and long-term complications, alternatives available to the recipient and uncertainty in outcomes. The donor must also understand that recipient benefit is not guaranteed. A complete discussion connects risk to the donor's circumstances and checks comprehension; a general statement that surgery has risks is insufficient.
Apply it
A donor says the only consequence will be a short hospital stay. Explore work absence, recovery support, potential complications and emotional effects, then ask the donor to describe how donation could affect life after discharge.
Common pitfall: Focusing exclusively on recipient survival can minimize the donor's independent interests. Absence of a precise individual risk estimate does not justify omitting uncertainty or possible serious harm.
6.How are a living donor's withdrawal and confidentiality protected?
A potential living donor may decline or withdraw from donation, and the decision must remain free from coercion. Confidential handling of the donor's information supports this freedom, particularly when the intended recipient is a relative. The coordinator should create an opportunity for private communication and explain how withdrawal can be handled without disclosing confidential details to the recipient. Willingness expressed in front of family does not resolve later concerns or eliminate the donor's right to stop.
Apply it
A sibling privately says they no longer want to donate but fears family blame. Acknowledge the decision, involve the donor team and advocate, and explain confidential communication options without asking the recipient to approve withdrawal.
Common pitfall: Requiring the donor to justify withdrawal to the recipient undermines voluntariness. Protecting confidentiality does not authorize disclosure of a fabricated diagnosis as an explanation for stopping.
7.Why does a living donor need independent advocacy?
The donor's interests can differ from the recipient's interests, even when both strongly desire transplantation. Independent donor advocacy helps protect informed, voluntary decision-making and provides a route for discussing pressure, uncertainty and concerns about donation. The advocate's role is centered on the donor rather than obtaining an organ for the recipient. A donor who hesitates needs space to explore that hesitation; enthusiasm from the recipient's team cannot establish donor readiness.
Apply it
A recipient's family repeatedly calls a prospective donor about completing tests. Explain the advocate's role, offer a private donor conversation and assess whether the donor feels able to pause or decline without losing support.
Common pitfall: Using the advocate primarily to persuade a hesitant donor reverses the purpose of advocacy. Family agreement and a close relationship do not establish that donation is voluntary.
8.Which early living donor problems require explicit teaching?
Living donor education should distinguish expected recovery needs from possible complications. Pain management, incision care, activity restrictions and follow-up testing belong in the recovery plan; bleeding, infection and uncontrolled pain require a clear reporting pathway. Teaching should explain what action to take and whom to contact rather than merely naming complications. The important boundary is that an expected postoperative symptom can still require reassessment when it worsens, becomes uncontrolled or accompanies other concerning changes.
Apply it
A donor expects some incision discomfort but later reports increasing pain and fever. Use the discharge escalation plan to arrange prompt assessment, and reinforce that a worsening pattern should not be accepted as routine recovery.
Common pitfall: Saying that pain is normal after surgery can delay reporting of a complication. Teaching a list of risks without contact instructions leaves the donor unable to act.
ABTC Candidate Handbook — currently linked August 13, 2026 PDF · OPTN Guidance for the Informed Consent of Living Donors
9.Why should emotional recovery be discussed with living donors?
Living donation can have psychological consequences, including anxiety, depression, guilt and distress related to recovery or the recipient's outcome. Education should normalize reporting emotional difficulty without suggesting that it is inevitable. A technically successful donation does not establish psychological well-being. The useful decision is whether a donor needs additional assessment and support, based on symptoms and their effect on daily functioning, rather than whether the donor previously appeared motivated or satisfied.
Apply it
A donor with an uncomplicated operation describes persistent guilt after the recipient loses the graft. Arrange psychosocial follow-up, assess how distress affects daily life and explain that donor support remains appropriate despite successful surgical recovery.
Common pitfall: Reassuring the donor solely that the operation went well can dismiss meaningful distress. Recipient outcomes and the donor's emotional recovery require related but separate assessments and support.
OPTN Guidance for the Informed Consent of Living Donors · ABTC Candidate Handbook — currently linked August 13, 2026 PDF
10.How do required living donor reporting checkpoints differ from clinical follow-up?
U.S. OPTN policy requires living donor follow-up reporting for at least two years, with checkpoints at six months, one year and two years after donation. These program reporting obligations do not define the complete clinical care schedule or end the donor's need for lifelong health care. Additional visits and tests depend on recovery, findings and the donor's health needs. Surgical healing therefore differs from both required reporting and ongoing assessment of physical and psychological health.
Apply it
A donor asks whether a healed incision means all follow-up can stop. Explain the six-month, one-year and two-year reporting checkpoints, arrange any additional clinical assessment needed and identify who will provide ongoing health care after the reporting period.
Common pitfall: Presenting two years as the endpoint of donor health care confuses reporting duration with clinical need. The three reporting checkpoints also do not replace additional visits or tests required by symptoms or recovery.
OPTN Policies — effective October 1, 2026 · OPTN Guidance for the Informed Consent of Living Donors
11.Why must antirejection treatment continue when a recipient feels well?
Immunosuppressive medicines reduce immune injury to the transplanted organ; their purpose continues after symptoms resolve and laboratory results improve. A recipient may feel well while remaining at risk of rejection. Education should connect consistent administration, refill planning and follow-up monitoring to protection of the graft. The key decision is to contact the transplant team about adverse effects or access problems rather than independently stopping therapy because the recipient feels healthy or fears a complication.
Apply it
A liver recipient plans to stop antirejection treatment after normal laboratory results. Explain that the results may reflect effective treatment, ask about adverse effects and costs, and have the recipient describe the plan for ongoing doses.
Common pitfall: Calling immunosuppression temporary can encourage dangerous self-discontinuation. Explaining adherence without exploring affordability or adverse effects may leave the actual reason for missed treatment unresolved and recurrent.
12.How do hyperacute, acute and chronic rejection differ?
Hyperacute rejection results from preexisting antibodies reacting with donor antigens, producing rapid vascular injury and thrombosis soon after transplantation. Acute rejection may involve T-cell injury, antibody-mediated injury or both; it can occur later as well as early, especially with inadequate immunosuppression. Chronic immune injury contributes to progressive vascular damage, fibrosis and loss of function. Timing supplies a clue, but mechanisms, tissue findings and organ function determine interpretation. A late abnormal result cannot be assumed to represent irreversible chronic rejection solely because years have passed.
Apply it
A recipient several years after transplantation develops graft dysfunction after missed treatment. Explain that acute rejection remains possible and that laboratory assessment, relevant antibody testing and tissue evaluation may be needed to distinguish causes.
Common pitfall: Equating acute with early and chronic with every late problem confuses timing with mechanism. Symptoms or elapsed time alone cannot establish rejection type or reversibility.
KDIGO 2009 Kidney Transplant Recipient Guideline: Summary · ISHLT Guidelines for the Care of Heart Transplant Recipients — published May 2023
13.How should recipients understand overlapping infection and rejection warnings?
Fever, organ-related discomfort or declining organ function can signal complications without identifying a single cause. Infection and rejection require different evaluation and treatment, so education should emphasize early reporting rather than patient self-diagnosis. The recipient should know which symptoms trigger contact and which require emergency care. The discriminating principle is that a warning sign initiates assessment; neither symptoms alone nor the patient's previous experience establishes whether additional immunosuppression or antimicrobial treatment is appropriate.
Apply it
A recipient with fever assumes the problem is rejection because a previous episode felt similar. Instruct the patient to obtain prompt assessment and communicate symptoms, timing and medicines rather than using leftover treatment without evaluation.
Common pitfall: Teaching that fever always means rejection can promote inappropriate self-treatment. Giving an undifferentiated warning list without urgency or contact instructions also weakens the recipient's ability to respond.
ABTC Candidate Handbook — currently linked August 13, 2026 PDF · NHS Blood and Transplant: Warning Signs After a Lung Transplant
14.Which food and cheese choices reduce avoidable infection exposure?
Immunosuppressed recipients are more vulnerable to foodborne illness. Safer choices include thoroughly cooked meat and seafood, washed produce and specific pasteurized cheeses such as cheddar or mozzarella. Pasteurization alone does not make every cheese a safer choice: unheated queso fresco-type cheeses made from either pasteurized or unpasteurized milk and unheated deli-sliced cheeses are riskier. CDC advises heating applicable queso fresco-type, soft and deli-sliced cheeses to 165°F or until steaming hot. Safe storage and prevention of cross-contamination also matter.
Apply it
A recipient plans raw oysters and cold pasteurized queso fresco. Suggest cooked seafood and pasteurized cheddar or mozzarella. Explain that queso fresco-type cheese remains risky when unheated and that applicable soft or deli-sliced cheeses should reach 165°F or steaming hot.
Common pitfall: Treating a pasteurized-milk label as sufficient for every cheese overlooks cheese type and handling. Fresh appearance or a restaurant's reputation also cannot establish pathogen control.
CDC Safer Food Choices for People With Weakened Immune Systems
15.How do live and non-live vaccines differ during immunosuppression?
Live vaccines contain organisms capable of replication and can pose safety concerns in people with substantial immune suppression. Non-live vaccines cannot cause infection through replication of a vaccine organism, although the immune response may be reduced. Vaccine decisions therefore require both a safety assessment and attention to effectiveness and timing. The discriminating questions are the vaccine type and the recipient's immune status, rather than a blanket assumption that every vaccine is unsafe after transplantation.
Apply it
A recipient is offered a live vaccine at a community clinic. Ask the clinic to coordinate with the transplant team before administration, while explaining that non-live vaccines raise different safety and response considerations under immunosuppression.
Common pitfall: Calling every vaccine contraindicated can prevent useful protection. Calling a non-live vaccine safe does not guarantee an adequate immune response or establish the best timing for administration.
16.Why does skin protection matter across skin tones?
Transplant-related immune suppression increases skin cancer risk, and people with darker skin can also develop skin cancer. Education should combine sun protection with attention to changing, unusual or nonhealing skin findings. The discriminating clue is a concerning lesion or change, rather than skin tone alone. Protective clothing, shade and appropriate sunscreen support prevention, while reporting a persistent abnormality supports evaluation. Prevention counseling should avoid suggesting that any skin color makes surveillance unnecessary.
Apply it
A recipient with dark skin believes sunscreen and skin checks are irrelevant. Explain the added risk associated with transplantation and ask the patient to identify a practical sun-protection plan and changes they would report.
Common pitfall: Restricting counseling to fair-skinned recipients misses others at risk. Sun protection also cannot substitute for evaluation of an existing nonhealing lesion or another persistent suspicious skin change.
17.How should lung recipients use home monitoring?
Home spirometry and symptom monitoring help lung recipients recognize changes that warrant contact with the transplant service. A decline from the individual's established measurements, new breathlessness, fever or a worsening cough should be interpreted as a warning requiring assessment. A measurement cannot by itself distinguish infection from rejection. Education should connect monitoring to a reporting plan, including the recipient's baseline and prescribed thresholds, rather than asking the patient to collect numbers without knowing what to do.
Apply it
A lung recipient records lower readings over several days but waits because there is no fever. Explain that a change from baseline still matters and have the patient describe how and when to report the trend.
Common pitfall: Waiting for every warning sign to occur together delays assessment. Avoid supplying one universal spirometry cutoff when the recipient's established monitoring plan provides individualized reporting instructions and thresholds.
NHS Blood and Transplant: Warning Signs After a Lung Transplant
18.How can support persons help without replacing recipient understanding?
Support persons can help with appointments, medication organization, transportation and recognition of warning signs. Education should clarify who will perform each task and verify understanding with the recipient as well as the support person whenever possible. A caregiver's confidence does not establish that the recipient understands the plan or that help will remain available. The discriminating issue is whether responsibilities and backup arrangements are explicit enough to work during an ordinary day and an unexpected problem.
Apply it
A spouse manages every appointment but will soon return to work. Ask the recipient to explain the next visit and contact plan, then identify who can help with transportation and urgent communication during the spouse's absence.
Common pitfall: Directing all teaching to a caregiver can conceal the recipient's knowledge gaps. Assuming one named helper is always available leaves predictable absences and backup needs unaddressed during recovery.
AHRQ RED Toolkit, Tool 3: Delivering the Re-Engineered Discharge · AHRQ Tool: Teach-Back
19.Why must routine health maintenance continue after transplantation?
Transplant follow-up addresses graft health, but recipients also need ongoing attention to general health and complications associated with long-term treatment. Cancer screening, bone health, metabolic concerns, dental care and primary care belong within a coordinated plan. The educational decision is to clarify which clinician manages each need and how findings reach the transplant service. A stable graft does not establish that the recipient has no other important health risks or preventive care needs.
Apply it
A recipient attends every transplant visit but has stopped primary care appointments. Review preventive and chronic disease needs, identify responsible clinicians and explain how the transplant and primary care teams will exchange relevant results and medication changes.
Common pitfall: Assuming that frequent transplant visits automatically cover all preventive care creates gaps. Avoid promising one universal screening schedule without considering age, history and the applicable clinical recommendations.
NIDDK Living with a Liver Transplant · ABTC Candidate Handbook — currently linked August 13, 2026 PDF
Pre-Transplant Evaluation and Management30%
20.When should active infection delay kidney transplantation, and what is the hepatitis C exception?
KDIGO recommendation 10.1.1 advises delaying kidney transplantation until active infections are treated, explicitly excluding hepatitis C from this general rule. Hepatitis C treatment timing can be coordinated before or after transplantation according to the transplant and antiviral plan. A symptomatic bacterial infection, such as a urinary tract infection, requires treatment and reassessment because immunosuppression can worsen uncontrolled infection. Distinguish active infection from a historical diagnosis or colonization, and distinguish the named hepatitis C exception from permission to overlook other active infections.
Apply it
A kidney candidate develops dysuria, fever and a culture-confirmed bacterial UTI. Communicate the infection, antimicrobial treatment and clinical response, and arrange reassessment before transplantation. Do not apply the hepatitis C timing exception to this bacterial infection.
Common pitfall: Treating hepatitis C viremia as an automatic requirement to complete therapy before transplantation misstates the exception. Conversely, the exception does not remove the need for an explicit antiviral treatment plan.
KDIGO 2020 Guideline on Evaluation and Management of Candidates for Kidney Transplantation
21.How should adherence concerns affect candidate evaluation?
Adherence assessment should identify barriers and determine whether education, counseling or practical support can address them. KDIGO advises against excluding kidney candidates solely for a history of nonadherence, except when ongoing health-compromising behavior persists despite intervention. The discriminating distinction is between past difficulty with a remediable cause and continuing harmful behavior after appropriate support. A useful evaluation documents what happened, why it happened, what intervention was attempted and the resulting behavior.
Apply it
A candidate missed dialysis because transport repeatedly failed. Confirm the barrier, involve social work, arrange reliable transport and reassess attendance. Present the response to intervention instead of summarizing the history only as poor adherence.
Common pitfall: A character label can obscure poverty, misunderstanding or treatment burden. Prior difficulty also should not be dismissed when current harmful behavior continues despite targeted education and support interventions.
KDIGO 2020 Guideline on Evaluation and Management of Candidates for Kidney Transplantation
22.When should progressive kidney disease trigger transplant evaluation?
KDIGO recommends informing and considering patients with CKD G4–G5 who are expected to reach kidney failure for transplantation. Referral should allow time for evaluation and possible living donor workup before dialysis becomes necessary; the guideline recommends referral at least six to twelve months before anticipated dialysis initiation. Kidney transplantation treats advanced irreversible kidney failure, whereas a potentially reversible acute kidney injury requires a different assessment. Referral, acceptance and listing are separate decisions, and referral does not establish immediate eligibility.
Apply it
A patient has progressive CKD with eGFR 19 mL/min/1.73 m² and is expected to need dialysis within the coming year. Initiate transplant education and referral while dialysis planning continues rather than waiting for dialysis to begin.
Common pitfall: Waiting until dialysis starts can lose evaluation time and a chance for preemptive transplantation. A low eGFR caused by an acute reversible process does not by itself establish an indication for chronic kidney transplantation.
KDIGO 2020 Guideline on Evaluation and Management of Candidates for Kidney Transplantation
23.Which findings distinguish a remediable barrier from a major kidney transplant contraindication?
KDIGO recommendation 11.2.1 generally excludes active malignancy, with exceptions including superficial nonmelanoma skin cancer, prostate cancer with Gleason score 6 or lower, and incidentally detected renal tumors no larger than 1 cm. Cancer characteristics and the treatment plan still require assessment; an exception is not automatic clearance. Recommendation 13.7 advises excluding candidates with uncorrectable symptomatic NYHA III/IV cardiac disease, including severe coronary disease, left ventricular ejection fraction below 30% or severe valvular disease, unless mitigating factors give acceptable estimated survival according to national standards. Obesity alone is not an equivalent exclusion.
Apply it
A candidate with BMI 34 kg/m², preserved functional capacity and a superficial nonmelanoma skin cancer needs documented cancer management and individualized surgical and nutritional assessment. A second candidate has persistent NYHA IV symptoms, ejection fraction 25% despite optimized treatment, no corrective option and no mitigating survival factors; this fits the qualified cardiac exclusion recommendation for kidney transplantation alone.
Common pitfall: Treating every cancer as equivalent misses explicit low-risk exceptions. Using ejection fraction alone also omits the symptomatic, uncorrectable disease context and mitigating-survival qualification. These are kidney-candidate recommendations, not universal exclusion rules for every organ.
KDIGO 2020 Guideline on Evaluation and Management of Candidates for Kidney Transplantation
24.Why does elevated pulmonary vascular resistance change heart transplant assessment?
Pulmonary hypertension before heart transplantation can expose the donor right ventricle to excessive afterload and increase the risk of postoperative right ventricular failure. Right heart catheterization measures the hemodynamic problem, and assessment of reversibility helps distinguish pressure elevation that improves with treatment from a persistent barrier. Diuresis, selected vasoactive therapies and mechanical circulatory support may improve hemodynamics in appropriate patients. A pressure measurement therefore needs interpretation alongside pulmonary vascular resistance, filling pressures, treatment response and the candidate's overall condition.
Apply it
A heart candidate's elevated pulmonary pressures improve after hemodynamic optimization. Present the before-and-after catheterization findings and treatment response. A different candidate with persistently elevated resistance requires further risk assessment rather than the same conclusion based on one shared pressure value.
Common pitfall: Treating every elevated pulmonary pressure as irreversible overlooks potentially modifiable disease. Ignoring persistent resistance can underestimate the load the donor right ventricle must tolerate.
ISHLT Guidelines for the Care of Heart Transplant Recipients — published May 2023
25.Why must donor suitability be assessed separately from recipient need?
A recipient's need for transplantation does not establish that a particular person can safely and voluntarily donate. Donor evaluation considers medical suitability, understanding, psychological circumstances and freedom from coercion, with confidentiality protections. The decision must preserve the donor's interests even when the recipient's illness is urgent. The discriminating cue is evidence about the donor's own risk and willingness; urgency can shape logistics but cannot supply missing consent or eliminate an unresolved donor safety concern.
Apply it
A recipient deteriorates while a donor evaluation remains incomplete. Communicate the urgency to the donor team, but identify the outstanding donor assessments and preserve the donor's private opportunity to decline rather than presenting donation as an obligation.
Common pitfall: Using recipient urgency to bypass donor concerns creates a conflict of interests. A close family relationship does not substitute for independent evaluation, adequate understanding or voluntary consent.
26.How should selection recommendations become an actionable plan?
A recommendation becomes useful when the candidate understands the required action, its purpose, who will help and how progress will be reassessed. Communication should distinguish a request for additional work from a completed listing decision. Teach-back can reveal whether the candidate understands the next step. The discriminating issue is whether there is a feasible route to completion, rather than whether the team has issued instructions. Referrals and practical support should match the barrier identified.
Apply it
A candidate hears 'more evaluation needed' and believes transplantation has been permanently refused. Explain the specific additional consultation, why it matters, how it will be arranged and what information the team will review afterward.
Common pitfall: Vague instructions can sound like permanent rejection or guaranteed acceptance. A written task list alone does not establish that the patient understands the plan or can complete it.
ABTC Candidate Handbook — currently linked August 13, 2026 PDF · AHRQ Tool: Teach-Back
27.What does inactive waitlist status mean?
Under U.S. OPTN rules, an inactive candidate remains registered but is not eligible to receive organ offers while inactive. Inactivation differs from removal from the waiting list. Waiting-time consequences depend on the applicable organ policy and should not be generalized across organs. The coordinator must explain the reason, necessary actions and reassessment plan. The discriminating point is offer eligibility: remaining on the list does not mean the candidate can currently receive an offer.
Apply it
A registered candidate is temporarily inactive during treatment of an illness and asks whether an organ could arrive tomorrow. Explain the effect on offers and the steps required for reassessment, using the relevant organ's rules for waiting time.
Common pitfall: Equating inactive status with removal misstates registration. Promising that every inactive candidate accrues the same waiting-time credit ignores differences among organ allocation policies and eligibility conditions.
28.Why does waitlist maintenance require current information?
Listing is an ongoing process because illness, laboratory findings, contact information and other eligibility-related circumstances can change. Accurate current information supports allocation and safe response to an offer. Coordinators must validate documentation, communicate relevant changes and amend status according to applicable OPTN policy. The discriminating issue is whether the recorded information still represents the candidate, rather than whether it was accurate at initial listing. A completed original evaluation cannot guarantee continuing readiness for transplantation.
Apply it
A candidate reports a recent hospitalization after the routine waitlist review was completed. Obtain the current records, alert the transplant team and determine whether status or required follow-up must change before treating the candidate as ready.
Common pitfall: Waiting for an annual review can leave consequential changes unaddressed. Updating a local note without ensuring required waitlist records and patient communication are completed creates inconsistent information.
ABTC Candidate Handbook — currently linked August 13, 2026 PDF · OPTN Policies — effective October 1, 2026
29.What does MELD communicate about a liver candidate?
MELD supports assessment of medical urgency for liver allocation using specified clinical inputs. The current adult calculation incorporates bilirubin, INR, creatinine, sodium, albumin and sex, with additional calculator instructions and applicable dialysis information. It does not summarize every feature of transplant suitability or guarantee an individual waiting time. The discriminating task is to use the applicable calculator with accurate, current inputs and required context rather than estimate urgency from one laboratory value.
Apply it
A liver candidate's sodium and albumin have changed since the last calculation. Verify the complete required inputs and dialysis information, calculate using the applicable OPTN tool and communicate the updated result without promising a date for transplantation.
Common pitfall: Using only bilirubin ignores the multivariable calculation. Substituting an older formula or treating the score as a complete suitability assessment can misrepresent the candidate's allocation and clinical situation.
30.What does cPRA estimate?
Calculated panel reactive antibody estimates the proportion of donors expected to carry one or more antigens listed as unacceptable for a candidate. It describes the breadth of sensitization in relation to a donor population, not the probability of rejecting one particular graft. A high cPRA suggests fewer immunologically acceptable donors. The discriminating distinction is between population-level access information and donor-specific compatibility, which requires the relevant antibody and matching assessment for the actual offer.
Apply it
A candidate with cPRA of 98% believes every offered kidney has a 98% chance of rejection. Explain the population estimate, then clarify that the actual donor's antigens and compatibility evaluation determine the offer-specific immunologic assessment.
Common pitfall: Reading cPRA as a direct rejection probability misuses the number. A low cPRA also cannot independently establish compatibility with a particular donor carrying an unacceptable antigen.
31.Why should sensitizing events be reported during waiting?
Pregnancy, transfusion and prior transplantation can expose a person to nonself antigens and are important sensitization history. Changes in antibody information can affect unacceptable antigens and assessment of a potential donor. The coordinator should communicate a new event to the transplant and histocompatibility teams so they can determine the necessary reassessment. The discriminating cue is a relevant new exposure after earlier testing; an old compatibility assessment may not reflect the candidate's current antibody profile.
Apply it
A waiting kidney candidate receives a transfusion during an outside hospitalization. Document the event and notify the transplant and HLA teams so they can determine whether updated samples or antibody assessment are needed before interpreting a later offer.
Common pitfall: Assuming that an unchanged blood group means unchanged immunologic risk overlooks HLA sensitization. Reporting the event does not itself establish that new antibodies have definitely developed after exposure.
32.How does crossmatching differ from cPRA?
Crossmatching evaluates donor-recipient immunologic compatibility, including whether recipient antibodies react with donor cells in a physical crossmatch. cPRA instead estimates how broadly unacceptable antigens limit the donor population. These measures answer different questions and cannot substitute for each other. The discriminating cue is a specific donor: compatibility decisions require the applicable donor-specific assessment and interpretation by the transplant and histocompatibility teams, rather than reassurance from the candidate's overall sensitization percentage.
Apply it
A candidate has a low cPRA but a concerning donor-specific crossmatch result. Communicate the result and relevant antibody information for specialist interpretation rather than describing the offer as compatible solely because the population sensitization estimate is low.
Common pitfall: Using cPRA as a substitute for crossmatching confuses population access with donor-specific risk. A positive result requires interpretation; the coordinator should not independently prescribe a desensitization strategy.
33.Why do blood group and HLA compatibility require separate review?
ABO blood group information and HLA antibody information describe different immunologic considerations. An acceptable blood group relationship does not establish that the recipient lacks antibodies against the donor's HLA antigens. Offer review also includes organ-specific factors such as size and the candidate's current condition. The discriminating principle is that one favorable matching feature cannot establish overall suitability. Specialized incompatible-transplant approaches require their own evaluation and do not erase the need to recognize and communicate incompatibility.
Apply it
An offer has an acceptable ABO relationship, but the donor carries an antigen listed as unacceptable. Present both facts to the transplant and HLA teams rather than reassuring the candidate that blood group matching has resolved compatibility.
Common pitfall: Treating ABO compatibility as complete matching overlooks other immune barriers. Conversely, an incompatibility should trigger the appropriate specialist assessment rather than an improvised coordinator-led workaround or treatment plan.
OPTN Patient Glossary · OPTN CPRA Calculator · ABTC Candidate Handbook — currently linked August 13, 2026 PDF
34.How do deceased donor categories differ?
Donation after brain death follows death determined by permanent loss of all brain function, including brainstem function. Donation after circulatory death follows death determined by permanent cessation of circulation and breathing. These categories describe the basis for death determination before deceased organ donation; living donation involves a living donor. Neither deceased donor category independently establishes organ suitability or transmissible infection risk. Offer review must separately consider the donor category, findings about the offered organ, donor infection history and testing, and the intended recipient.
Apply it
A candidate assumes that a circulatory-death donor had a transmissible infection. Explain that the designation concerns permanent cessation of circulation and breathing. Then discuss the donor's infection testing and organ findings separately rather than inferring them from the death-determination category.
Common pitfall: Confusing donor category with infection status can distort acceptance decisions. Brain death includes permanent loss of brainstem function; circulatory death concerns permanent cessation of circulation and breathing. Neither designation alone means that an organ is infected, unsuitable or appropriate for every recipient.
SRTR Getting a Transplant · ABTC Candidate Handbook — currently linked August 13, 2026 PDF
35.Why can negative donor infection testing leave residual risk?
A recently acquired infection may fall within a window period before the relevant test becomes positive. Negative donor testing therefore reduces uncertainty without proving zero transmission risk. The donor's recent history, test type and timing remain relevant to informed discussion and recipient monitoring. The discriminating clue is a possible recent exposure despite negative results. Education should explain residual risk without implying that every donor with a reported risk factor is infected or that transmission is inevitable.
Apply it
A candidate asks whether negative donor HIV, HBV and HCV tests guarantee no transmission. Explain the window-period limitation and the planned recipient testing, then check understanding of the difference between residual possibility and documented infection.
Common pitfall: Promising zero risk overstates what testing can establish. Treating a donor history criterion as a positive infection diagnosis makes the opposite error and distorts the offer discussion.
36.Which hepatitis B tests establish the pretransplant baseline?
The 2020 U.S. Public Health Service guideline specifies hepatitis B surface antigen, total hepatitis B core antibody and hepatitis B surface antibody in pretransplant recipient testing. These markers provide different information about current infection, prior exposure and immunity; a single negative surface antigen result does not replace the full assessment. The discriminating task is to verify the complete baseline panel and route abnormal findings for interpretation, rather than treating every hepatitis B result as interchangeable.
Apply it
A recipient's preoperative record contains a negative surface antigen result but no core or surface antibody results. Identify the missing baseline components and coordinate completion and review before presenting the hepatitis B assessment as complete.
Common pitfall: Using surface antigen alone leaves exposure and immunity information unresolved. A positive antibody result also requires identifying which antibody was measured before interpreting its significance for the recipient.
37.What must a preoperative coordination handoff resolve?
Preoperative coordination brings together the candidate's current condition, required compatibility assessment, consent, relevant tests and the readiness of participating departments. Blood bank, HLA laboratory, operating room, admitting and postoperative teams need consistent information. The discriminating question is whether a safety-critical issue is resolved and communicated, rather than whether an operating time has been reserved. New symptoms or missing results must reach the responsible clinicians before an earlier plan is treated as authorization to proceed unchanged.
Apply it
A recipient arrives for an accepted offer and reports a new fever while final testing is pending. Alert the responsible transplant clinicians, clarify the outstanding results and coordinate the reassessment with admissions and the operative team.
Common pitfall: Allowing logistical momentum to substitute for clinical readiness can carry unresolved risk into surgery. A completed handoff must distinguish pending information from verified results and assigned follow-up actions.
ABTC Candidate Handbook — currently linked August 13, 2026 PDF
Post-operative Monitoring, Evaluation, and Reporting39%
38.How should a persistent creatinine rise be interpreted after kidney transplantation?
A persistent, unexplained increase in serum creatinine signals possible kidney allograft dysfunction and warrants investigation. KDIGO recommends allograft biopsy for a persistent unexplained increase, with assessment for reversible causes informing the evaluation. Creatinine identifies a change in function but does not establish rejection by itself. The discriminating clue is a sustained departure from the recipient's baseline after relevant context has been considered, rather than a single universal threshold or the presence of graft pain.
Apply it
A kidney recipient has a confirmed creatinine increase on repeat testing without a clear explanation. Communicate the trend, baseline, medication information and associated findings, and coordinate the clinician-directed evaluation rather than waiting for pain or fever.
Common pitfall: Labeling every rise as rejection can bypass other causes. Reassurance based on absent symptoms can also delay evaluation of a persistent change that meets investigation criteria.
39.Why does new proteinuria matter in a kidney recipient?
New-onset proteinuria can indicate kidney allograft pathology even when creatinine remains near baseline. KDIGO recommendation 9.5 suggests kidney allograft biopsy for either new-onset proteinuria or unexplained proteinuria of at least 3 g/g creatinine or 3 g/24 hours. These are separate indications: new-onset proteinuria does not have to reach the 3 g threshold to meet the suggested biopsy indication. Proteinuria is a finding requiring investigation, not confirmation of rejection or another specific diagnosis.
Apply it
A recipient previously without proteinuria develops a urine protein-to-creatinine ratio of 0.8 g/g while creatinine remains stable. Verify and communicate the result and prior measurements, and coordinate evaluation for the new-onset proteinuria biopsy indication. Separately, unexplained proteinuria of 3.2 g/g meets the quantitative indication even if it is not newly developed.
Common pitfall: Applying the 3 g threshold to every case misses the independent new-onset indication. Stable creatinine does not exclude clinically important graft pathology. KDIGO suggests biopsy to investigate these findings; the urine result itself neither establishes the underlying diagnosis nor automatically justifies rejection treatment.
40.How does ultrasound help distinguish surgical causes of kidney graft dysfunction?
Urinary obstruction, impaired perfusion and a compressive postoperative fluid collection can reduce kidney graft function without primary immune injury. Ultrasound contributes structural information; Doppler assessment adds information about blood flow. Hydronephrosis or a collection directs attention toward a surgical or urologic problem, whereas a normal scan does not exclude rejection. Sirolimus-associated impaired wound healing and increased lymphocele risk make medication history relevant when a collection develops. Imaging and biopsy answer different questions and may both be needed.
Apply it
A kidney recipient develops oliguria, rising creatinine and new graft-region swelling. Communicate the abrupt change and coordinate urgent surgical review and ordered graft ultrasound with flow assessment. If a collection or obstruction is identified, track the intervention and subsequent urine output and creatinine; persistent unexplained dysfunction still requires further evaluation.
Common pitfall: A collection is not automatically infected, and a normal ultrasound does not establish a normal graft. Moving directly to rejection treatment without assessing obstruction or perfusion can delay correction of a surgical cause.
KDIGO 2009 Kidney Transplant Recipient Guideline: Summary · DailyMed - SIROLIMUS tablet, film coated
41.How do maintenance antimetabolites protect the graft, and what adverse effects distinguish them?
Antimetabolites suppress lymphocyte proliferation and commonly complement a calcineurin inhibitor in maintenance immunosuppression. Mycophenolate inhibits de novo guanine nucleotide synthesis; important adverse effects include diarrhea and bone marrow suppression, and fetal toxicity makes pregnancy planning essential. Azathioprine is an alternative purine antimetabolite with marrow and liver toxicity risks. Its interaction with allopurinol can cause severe myelosuppression unless specifically managed. A low leukocyte count requires review of the complete regimen because other medicines and infection can also contribute.
Apply it
A recipient taking mycophenolate develops diarrhea and leukopenia while receiving an antiviral. Review the medication timeline, CBC and infection findings with the transplant pharmacist and prescriber. Assess combined toxicity rather than automatically attributing both problems to one drug or advising self-discontinuation.
Common pitfall: Treating antimetabolites as interchangeable tablets overlooks distinct interactions and reproductive risks. Reducing immunosuppression without coordinated assessment can trade toxicity risk for inadequate graft protection.
KDIGO 2009 Kidney Transplant Recipient Guideline: Summary · DailyMed - MYCOPHENOLATE MOFETIL tablet, film coated · DailyMed - IMURAN- azathioprine tablet
42.When should a lung recipient's respiratory change trigger contact?
New or worsening breathlessness, cough, fever or a decline in home spirometry can indicate a post-lung-transplant problem. These findings require contact through the transplant service's escalation plan; severe respiratory distress requires emergency assessment. Symptoms and spirometry identify a need for evaluation but do not distinguish infection from rejection. The discriminating cue is a change from the recipient's usual status, especially when several findings occur together, rather than waiting for a definitive diagnosis at home.
Apply it
A lung recipient reports worsening cough and lower spirometry readings while denying fever. Arrange prompt transplant-team assessment using the reporting plan and obtain the trend and symptom details without requiring fever as an additional condition.
Common pitfall: Normal temperature does not make a respiratory decline harmless. Advising the recipient to adjust immunosuppression before assessment may obscure or worsen a problem whose cause remains undetermined.
NHS Blood and Transplant: Warning Signs After a Lung Transplant
43.How should urgent symptoms be separated from routine follow-up?
Posttransplant triage must recognize symptoms requiring emergency evaluation, including chest pain or severe breathing difficulty. The immediate decision concerns the level and timing of assessment, not a remote attempt to establish a precise diagnosis. A coordinator should direct the patient to emergency services when indicated and communicate relevant transplant information to the receiving clinicians. The discriminating clue is possible immediate threat to life or organ function, which cannot safely wait for a routine appointment or callback.
Apply it
A recipient calls with new severe chest pain and marked breathlessness. Direct activation of local emergency services, then communicate the transplant history and medication information to the appropriate team without delaying emergency assessment for administrative coordination.
Common pitfall: Asking the patient to wait for the next transplant clinic can delay time-critical care. Transplant-team notification supports emergency care but should not become a prerequisite for obtaining it.
ABTC Candidate Handbook — currently linked August 13, 2026 PDF
44.How do cellular and antibody-mediated rejection differ in mechanism and treatment consequences?
T-cell-mediated rejection involves cellular immune injury to the graft. Antibody-mediated rejection involves antibodies directed against donor antigens and associated endothelial or microvascular injury; donor-specific antibodies alone do not establish the tissue diagnosis. For kidney recipients, corticosteroids are initial treatment for acute cellular rejection, with lymphocyte-depleting treatment considered for resistant or recurrent episodes. Antibody-mediated treatment may include plasma exchange, IV immunoglobulin and additional immune-directed agents. Intensified therapy increases infection risk; corticosteroids can worsen glucose control, and lymphocyte-depleting agents can cause cytopenias.
Apply it
A kidney biopsy identifies cellular rejection, while another recipient has antibody-mediated findings and donor-specific antibodies. Anticipate different treatment plans. After therapy, track graft response, CBC, glucose and the prescribed infection-prevention plan rather than considering the episode complete when infusions finish.
Common pitfall: Assuming all rejection receives the same treatment ignores the immune mechanism and severity. Treating donor-specific antibody detection alone as proof of rejection can lead to inappropriate intensification.
KDIGO 2009 Kidney Transplant Recipient Guideline: Summary · ISHLT Guidelines for the Care of Heart Transplant Recipients — published May 2023
45.How should tacrolimus timing, interactions, formulation and toxicity be assessed together?
Interpret tacrolimus using the exact formulation, regimen, last dose time, collection time and clinical findings. For immediate-release PROGRAF given every 12 hours, collect the trough just before the next dose, approximately 12 hours after the previous dose. CYP3A inhibitors such as azole antifungals can raise exposure; inducers such as rifampin and St. John's wort can lower it. Grapefruit can increase concentrations and should be avoided. Starting or stopping an interacting agent requires review. Immediate-release and extended-release products require supervised conversion. Nephrotoxicity or neurotoxicity must be assessed alongside competing causes.
Apply it
A recipient develops tremor and rising creatinine after starting an azole; the reported trough was collected after the morning dose. Promptly communicate symptoms and the interaction, verify the dispensed formulation and arrange a correctly timed repeat concentration. The invalid trough does not remove the need for immediate clinical and interaction review.
Common pitfall: A post-dose value cannot be compared directly with a trough target. A concentration within an intended range does not exclude toxicity, and an elevated creatinine does not prove it. Independently withholding or increasing treatment can create a second problem while the cause remains unresolved.
PROGRAF Prescribing Information — revised July 2021 · KDIGO 2009 Kidney Transplant Recipient Guideline: Summary
46.Which postoperative findings distinguish bleeding, wound infection and impaired healing?
Postoperative blood loss reduces circulating volume and oxygen delivery; hypotension, tachycardia, increasing bloody drainage or a falling hemoglobin raise concern. Deep bleeding may occur without visible wound loss. Purulent drainage, spreading erythema and increasing localized pain favor wound infection, while separation of wound edges indicates dehiscence and requires assessment of depth. Sirolimus can impair angiogenesis and fibroblast proliferation, contributing to delayed healing and dehiscence. Hemodynamic assessment, serial blood counts, wound examination and targeted imaging or cultures address different possible complications.
Apply it
On the second postoperative day, a recipient develops blood pressure 86/52 mm Hg, increasing abdominal distension and a substantial hemoglobin decline. Activate immediate clinical assessment and notify the transplant surgeon while coordinating blood testing, blood-bank readiness and the requested investigation or operative response. Do not route this through routine wound follow-up.
Common pitfall: A clean external incision does not exclude internal hemorrhage. Conversely, delayed wound closure alone does not prove infection. Hemodynamic instability takes priority over obtaining a complete remote diagnosis or waiting for every laboratory result.
ABTC Candidate Handbook — currently linked August 13, 2026 PDF · DailyMed - SIROLIMUS tablet, film coated
47.How should liver graft injury be distinguished from vascular, biliary and immune complications?
Aminotransferase elevation indicates hepatocellular injury, while bilirubin and alkaline phosphatase trends help identify a cholestatic pattern; neither pattern establishes rejection. Hepatic artery thrombosis threatens graft perfusion and can cause graft loss. Rising INR adds concern about impaired synthesis, although anticoagulant use and other explanations must be considered. New graft abnormalities require review of postoperative timing, medications, infection findings and vascular or biliary causes. Vascular imaging addresses perfusion; biliary investigation addresses drainage; biopsy may be needed when immune injury remains suspected after other causes are assessed.
Apply it
A recent liver recipient develops an abrupt aminotransferase increase, rising INR and clinical deterioration. Escalate immediately to the liver transplant team and coordinate urgent assessment of graft blood flow rather than scheduling routine repeat laboratories. A stable recipient with a persistent cholestatic pattern needs directed biliary and other cause assessment rather than an automatic rejection diagnosis.
Common pitfall: Feeling well does not exclude liver graft abnormalities. Labeling every enzyme increase as rejection can delay recognition of a vascular emergency. Sirolimus labeling specifically warns of hepatic artery thrombosis and adverse outcomes in liver transplantation; medication exposure is relevant, not diagnostic.
NIDDK Living with a Liver Transplant · DailyMed - SIROLIMUS tablet, film coated · ABTC Candidate Handbook — currently linked August 13, 2026 PDF
48.How should early right ventricular failure be distinguished from other heart graft problems?
Elevated recipient pulmonary vascular resistance increases donor right ventricular afterload. Early right ventricular failure can produce venous congestion and inadequate forward flow, with hypotension, oliguria and rising right-sided filling pressure. Echocardiography evaluates right and left ventricular performance and pericardial fluid; invasive hemodynamics clarify filling pressures and cardiac output. This assessment helps distinguish right ventricular failure from broader graft dysfunction, inadequate filling or a mechanical complication. Rejection remains a separate possibility requiring its own diagnostic assessment; timing and low output alone do not establish it.
Apply it
A heart recipient with elevated pretransplant pulmonary resistance develops low output and venous congestion. Echocardiography shows right ventricular dilation with relatively preserved left ventricular function. Communicate the pretransplant hemodynamics and current findings urgently, and coordinate critical care, hemodynamic assessment and prescribed support rather than treating the pattern as isolated fluid excess.
Common pitfall: Low blood pressure does not prove that more fluid is needed, especially with high right-sided pressures. A normal left ventricular ejection fraction does not establish adequate overall graft performance. Do not label afterload-related right ventricular failure as primary graft dysfunction without excluding secondary causes.
ISHLT Guidelines for the Care of Heart Transplant Recipients — published May 2023 · 2022_guideline_ishlt_careofhtxrecipients.pdf
49.How should growth faltering be investigated in a pediatric heart transplant recipient?
Growth assessment requires serial age- and sex-appropriate measurements and growth velocity, not an adult BMI cutoff. Chronic cardiac dysfunction can increase metabolic demands while reducing intake and absorption; edema can make body weight appear reassuring. Record energy, protein and fluid intake, feeding symptoms, weight and length or height, with head circumference when age-appropriate. Falling growth velocity warrants nutritional and clinical assessment, including graft function when symptoms suggest cardiac impairment. Persistent feeding difficulty may require oral supplementation or enteral support; procedural feeding access requires multidisciplinary risk assessment.
Apply it
A young heart recipient's weight is unchanged, but length velocity has fallen and edema and feeding fatigue have appeared. Communicate the growth trajectory and symptoms, coordinate cardiac and dietitian assessment, and quantify actual intake. Increasing calories alone would not address possible cardiac dysfunction masked by fluid-related weight.
Common pitfall: One apparently acceptable weight does not establish normal growth or nutrition. Adult nutritional thresholds do not replace pediatric growth curves. Feeding support should be paired with investigation of the cause of deteriorating intake or growth.
2022_guideline_ishlt_careofhtxrecipients.pdf · ABTC Candidate Handbook — currently linked August 13, 2026 PDF
50.How do pancreas, intestine and combined transplants change interpretation of metabolic and gastrointestinal findings?
Combined transplantation requires separate assessment of each graft; stable kidney creatinine cannot establish pancreas function. In a kidney-pancreas recipient, new hyperglycemia requires review of pancreatic graft function alongside corticosteroid exposure, tacrolimus-associated metabolic effects and intercurrent illness. In an intestine recipient taking mycophenolate, diarrhea may reflect medication toxicity or infection and cannot establish rejection by itself. Mycophenolate can also cause marrow suppression and serious gastrointestinal injury. Assess stool changes, abdominal findings, fluid balance, CBC and medication chronology, and coordinate infection testing and organ-directed investigation with the relevant teams.
Apply it
A kidney-pancreas recipient develops hyperglycemia after rejection-treatment corticosteroids despite stable creatinine. Trend glucose, verify treatment exposure and arrange pancreas-team assessment without assuming either graft failure or harmless steroid effects. An intestine recipient with worsening diarrhea, leukopenia and abdominal pain needs prompt evaluation of hydration, infection and medication injury; severe pain or bleeding increases urgency and requires surgical assessment.
Common pitfall: One normal graft marker does not clear every transplanted organ. Assigning intestine-recipient diarrhea to mycophenolate without assessment can miss infection or another graft complication. Conversely, increasing immunosuppression solely because diarrhea might be rejection can worsen infection or toxicity.
ABTC Candidate Handbook — currently linked August 13, 2026 PDF · DailyMed - MYCOPHENOLATE MOFETIL tablet, film coated · PROGRAF Prescribing Information — revised July 2021 · ISHLT Guidelines for the Care of Heart Transplant Recipients — published May 2023
51.Which heart donor-recipient CMV pairing carries the highest serologic risk?
In heart transplantation, a CMV-seropositive donor and CMV-seronegative recipient, described as D+/R−, constitute the highest-risk serologic pairing. The recipient lacks prior immunity while the donor can provide a source of infection. This risk classification helps guide the prevention and monitoring plan but does not establish that disease is already present. The discriminating information is the paired donor and recipient serostatus, rather than a donor result or recipient symptom considered alone.
Apply it
A heart recipient is CMV negative and the donor is CMV positive. Identify the pairing as high risk, verify that the prescribed prevention and follow-up plan is communicated and avoid describing the serology as a diagnosis of active disease.
Common pitfall: Reading donor positivity as proof of recipient CMV disease confuses risk with diagnosis. Recipient seropositivity also does not mean that CMV prevention and clinical assessment are unnecessary.
ISHLT Guidelines for the Care of Heart Transplant Recipients — published May 2023
52.Why does EBV mismatch affect heart recipient monitoring?
An EBV-seronegative heart recipient receiving an organ from an EBV-seropositive donor is at risk for primary EBV infection and associated posttransplant lymphoproliferative disease. ISHLT guidance supports EBV DNA monitoring in relevant high-risk recipients. The serologic mismatch identifies surveillance needs; it does not diagnose lymphoproliferative disease. The discriminating approach integrates risk category, viral measurements and clinical findings, with specialist interpretation rather than applying one universal viral-load threshold across all laboratories and patients.
Apply it
A newly transplanted EBV-negative heart recipient has an EBV-positive donor. Ensure that the documented surveillance plan reaches the recipient and follow-up team, and explain that monitoring seeks evidence of a developing problem rather than proving cancer.
Common pitfall: Equating any detectable EBV DNA with established lymphoproliferative disease overstates the result. Ignoring the original mismatch can also leave a high-risk recipient's monitoring plan incompletely communicated.
ISHLT Guidelines for the Care of Heart Transplant Recipients — published May 2023
53.How do corticosteroid benefits and adverse effects shape follow-up?
Corticosteroids suppress inflammatory and immune responses and may be used in maintenance regimens and acute rejection treatment. Increased exposure can worsen hyperglycemia, blood pressure, mood and infection risk; prolonged exposure contributes to osteoporosis and other cumulative complications. The treatment role and duration therefore matter when interpreting a new problem. Stable graft function does not eliminate steroid-related harm, and steroid reduction must account for rejection risk and the prescribed taper rather than be driven by one adverse effect alone.
Apply it
A recipient develops elevated glucose and insomnia after corticosteroid treatment for rejection. Relate the timing to increased steroid exposure, coordinate glucose and symptom management, and verify the taper and infection-prevention plan while monitoring graft response.
Common pitfall: Assuming a short rejection-treatment course has no metabolic consequences can miss early harm. Independently stopping prolonged corticosteroid therapy also risks adrenal insufficiency and loss of immune protection.
KDIGO 2009 Kidney Transplant Recipient Guideline: Summary · ISHLT Guidelines for the Care of Heart Transplant Recipients — published May 2023 · NIDDK Living with a Liver Transplant
54.How do mTOR inhibitors differ from calcineurin inhibitors?
Sirolimus and everolimus inhibit mTOR signaling and lymphocyte proliferation. Tacrolimus and cyclosporine instead inhibit calcineurin-dependent T-cell activation. Selected regimens use mTOR inhibitors to permit calcineurin inhibitor reduction, but conversion introduces its own risks. Important mTOR adverse effects include impaired wound healing, proteinuria, dyslipidemia, mouth ulcers and cytopenias. The decision therefore considers wound status, urine protein, blood counts, lipids and graft risk rather than assuming that changing drug classes removes the need for toxicity monitoring.
Apply it
A recipient with kidney dysfunction is being considered for a regimen change but also has significant proteinuria and an unhealed wound. Include those findings in the discussion because they can weigh against immediate mTOR-based conversion despite concern about calcineurin inhibitor toxicity.
Common pitfall: Describing mTOR inhibitors as universally kidney-safe overlooks proteinuria and other adverse effects. Replacing a calcineurin inhibitor without an explicit immunosuppression and monitoring plan can compromise graft protection.
KDIGO 2009 Kidney Transplant Recipient Guideline: Summary · ISHLT Guidelines for the Care of Heart Transplant Recipients — published May 2023 · DailyMed - SIROLIMUS tablet, film coated
55.What does discharge medication reconciliation need to resolve?
Medication reconciliation compares the intended discharge regimen with prior and inpatient medicines, resolving omissions, duplications and conflicting instructions. The final plan should clearly identify what to start, continue, change or stop and how the patient will take each medicine. A list is not reconciled merely because it has been printed. The discriminating question is whether the instructions represent one coherent, verified regimen that the patient and receiving clinicians can follow without guessing between inconsistent versions.
Apply it
A recipient has two discharge lists with different tacrolimus instructions and a discontinued medicine on one list. Obtain clarification, issue a consistent final plan and use teach-back to verify what the recipient will take at home.
Common pitfall: Asking the patient to choose the newest-looking list transfers an unresolved prescribing problem. Teaching from contradictory instructions cannot make the regimen safe, even if the patient repeats them accurately.
AHRQ RED Toolkit, Tool 3: Delivering the Re-Engineered Discharge
56.How is medication access verified before discharge?
A prescription does not establish that a recipient can obtain and begin the medicine. Safe discharge planning verifies the dispensing pharmacy, availability, payment arrangements, required authorization and a workable supply for the transition home. Access barriers are clinical safety issues when they threaten interruption of essential treatment. The discriminating evidence is a realistic, confirmed acquisition plan rather than insurance coverage in principle. The coordinator should connect pharmacy, financial and clinical teams until the identified gap is resolved.
Apply it
A recipient's antirejection prescription requires prior authorization and the pharmacy cannot dispense it today. Coordinate with pharmacy, the prescriber and financial staff to establish an actual supply plan before treating medication preparation as complete.
Common pitfall: An insurance card or electronically transmitted prescription does not prove immediate access. Discovering an unavailable medicine only after the patient reaches home can create an avoidable treatment interruption.
AHRQ RED Toolkit, Tool 3: Delivering the Re-Engineered Discharge · ABTC Candidate Handbook — currently linked August 13, 2026 PDF
57.Why does inability to keep medicines down require prompt assessment?
Persistent vomiting can indicate illness and can prevent reliable administration of essential transplant medicines. The coordinator needs the symptom duration, associated findings, actual doses taken and ability to retain fluids and treatment. The decision concerns prompt assessment and a clinician-directed medication plan, rather than an unsupported assumption that the usual dose was absorbed or should be repeated. The discriminating cue is threatened continuity of treatment combined with the recipient's clinical condition and any emergency warning signs.
Apply it
A recent recipient has repeated vomiting and cannot retain antirejection medicines. Arrange prompt clinical contact or emergency assessment according to severity, report the last doses and symptom course, and avoid advising an automatic replacement dose.
Common pitfall: Treating vomiting only as a comfort issue misses the medication problem. Automatically repeating a dose assumes absorption information that is unavailable and may produce excessive exposure if absorption occurred.
NIDDK Living with a Liver Transplant · ABTC Candidate Handbook — currently linked August 13, 2026 PDF
58.How should transfer of care preserve monitoring responsibility?
A transfer is complete when the receiving team has the relevant history, current regimen, recent findings, pending tests and an explicit allocation of follow-up responsibilities. Merely sending records does not establish that someone will review the next result or renew essential medicines. The discriminating issue is ownership of each outstanding task. This is particularly important when several specialties or centers share care, because apparently duplicated follow-up can coexist with an unassigned critical result.
Apply it
A recipient moves to another region with a pending test and an upcoming refill. Confirm that the receiving clinicians accept responsibility for both, transmit the current regimen and explain to the patient whom to contact during the transition.
Common pitfall: Assuming that record transfer automatically transfers responsibility can leave results unreviewed. A vague instruction to follow up locally does not identify a clinician, appointment or workable medication plan.
AHRQ RED Toolkit, Tool 3: Delivering the Re-Engineered Discharge · ABTC Candidate Handbook — currently linked August 13, 2026 PDF
59.What posttransplant viral testing does U.S. OPTN Policy 15.3.C require?
For recipients without known HIV, HBV or HCV infection, OPTN Policy 15.3.C requires NAT for all three viruses within 28–56 days after transplantation. A recipient already known to have one infection is exempt from testing for that infection under this requirement, while the other required tests remain due. Liver recipients also require HBV NAT at 335–395 days, subject to the known-infection exception. These policy requirements differ from the 2020 PHS recommendation of testing at four to six weeks.
Apply it
Build a tracker that records preexisting infection status, each required NAT and its collection date, the 28–56-day window, and the additional 335–395-day HBV NAT for eligible liver recipients. For known HCV infection, retain required HIV and HBV testing rather than marking all viral surveillance exempt.
Common pitfall: Applying the known-infection exception to all three viruses omits required testing. Stopping the tracker after the early window misses the additional liver-recipient HBV requirement; clinical testing for an existing infection may still be needed separately.
OPTN Policies — effective October 1, 2026 · U.S. Public Health Service Guideline, 2020: Assessing Solid Organ Donors and Monitoring Transplant Recipients
60.How should an error in finalized OPTN follow-up data be corrected?
Verify the correct recipient, replacement information, dates and supporting source records. Under U.S. OPTN Policy 18.1.D, changes to finalized data require approval from the member's official OPTN Representative or designee. Both that approval and the reason for the correction must be reported in the data collection system before the changes are made. Obtaining approval or documenting a reason elsewhere does not complete this prerequisite. After these requirements are met, correct the finalized data through the applicable correction process.
Apply it
A finalized follow-up record contains an outdated creatinine value and an incorrect transfer date. Confirm the replacement entries against source documentation, obtain approval from the member's official OPTN Representative or designee, and report both the approval and correction reason in the data collection system. Only then change the finalized entries.
Common pitfall: A local chart amendment, replacement values or routine supervisory approval alone does not satisfy the finalized-data correction requirement. The authorized approver, the correction reason, their reporting within the data collection system and their completion before editing are distinct requirements. A later follow-up report also leaves the earlier erroneous record uncorrected.
OPTN Policies — effective October 1, 2026 · ABTC Candidate Handbook — currently linked August 13, 2026 PDF
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the published 31%/30%/39% domain emphasis, with slightly more study time for postoperative monitoring, evaluation and reporting.
- Practise explaining choices and risks, then verify understanding through teach-back rather than agreement.
- Distinguish transplant indications, remediable barriers and major contraindications using specified cancer exceptions, disease severity, reversibility and estimated survival.
- Separate population sensitization, donor-specific compatibility, donor category and transmissible-disease risk.
- Compare cellular and antibody-mediated rejection, their treatments and the infection, hematologic and metabolic consequences of intensified therapy.
- Connect maintenance medication mechanisms to characteristic adverse effects, interactions and monitoring needs.
- Interpret tacrolimus results using sample timing, formulation, interactions and clinical findings.
- Distinguish bleeding, obstruction, wound complications and vascular problems from immune graft injury; match each concern to the investigation it requires.
- Apply organ-specific reasoning to liver laboratory patterns, heart hemodynamics, lung respiratory trends, pediatric growth and combined-graft assessment.
- Track medication access, urgent escalation, result ownership, donor reporting checkpoints and qualified OPTN testing and correction requirements.
- Use the official outline to extend these selective lessons across the complete adult, pediatric, pancreas, intestine and multiorgan scope.
A practical preparation plan
1. Map the current outline
Use the CCTC outline effective July 1, 2026 to mark each task as familiar, partly familiar or unfamiliar. Keep the historical outline separate and identify gaps outside your usual organ service.
2. Build three decision notebooks
Organize notes under the exact three domains. For each topic, record the decisive finding, the coordinator's action, the responsible specialist and a tempting incorrect inference.
3. Rehearse education aloud
Explain transplant alternatives, donor withdrawal, medication continuity, food safety and warning signs in plain language. Follow each explanation with a teach-back request and correct one misunderstanding at a time.
4. Trace an offer and a complication
Work through candidate status, current illness, matching information, consent and departmental readiness. Then follow an abnormal postoperative result through differential assessment, relevant investigation, treatment consequences and documented follow-up.
5. Complete and review the drills
Answer the 20 questions before reading explanations. Review every distractor and classify errors as a knowledge gap, missed cue or incorrect inference; use the flashcards to revisit the underlying distinction.
6. Close scope and policy gaps
Return to unaddressed outline tasks, including less familiar organs and pediatric principles. Verify applicable OPTN requirements and organ-specific guidance before using policy timing or clinical protocols in practice.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABTC Candidate Handbook
- ABTC Candidate Handbook — currently linked August 13, 2026 PDF
- ABTC Certification Examinations
- ABTC Candidate Handbook — March 12, 2026 PDF
- AHRQ Tool: Teach-Back
- OPTN Guidance for the Informed Consent of Living Donors
- NIDDK Choosing a Treatment for Kidney Failure
- CDC Safer Food Choices for People With Weakened Immune Systems
- CDC Altered Immunocompetence
- NCI Skin Cancer on Black and Brown Skin
- OPTN CPRA Calculator
- OPTN Patient Glossary
- KDIGO 2020 Guideline on Evaluation and Management of Candidates for Kidney Transplantation
- OPTN MELD Calculator
- U.S. Public Health Service Guideline, 2020: Assessing Solid Organ Donors and Monitoring Transplant Recipients
- KDIGO 2009 Kidney Transplant Recipient Guideline: Summary
- PROGRAF Prescribing Information — revised July 2021
- ISHLT Guidelines for the Care of Heart Transplant Recipients — published May 2023
- NIDDK Living with a Liver Transplant
- NHS Blood and Transplant: Warning Signs After a Lung Transplant
- AHRQ RED Toolkit, Tool 3: Delivering the Re-Engineered Discharge
- OPTN Policies — effective October 1, 2026
- SRTR Getting a Transplant
- 2022_guideline_ishlt_careofhtxrecipients.pdf
- 2022_guideline_ishlt_careofhtxrecipients.pdf
- DailyMed - MYCOPHENOLATE MOFETIL tablet, film coated
- DailyMed - IMURAN- azathioprine tablet
- DailyMed - SIROLIMUS tablet, film coated
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.